Phase 3 Clinical Trial Results Lead to Approval of Oral Drug for Red Blood Cell Disorder

Recommended

FDA Approves Lisocabtagene Maraleucel for the Second-Line Treatment of Large B-Cell Lymphoma

Dabrafenib/Trametinib Combination Receives FDA Approval for BRAF V600E–Mutated Solid Tumors

FDA Approves Tisagenlecleucel for Adult Patients With Relapsed or Refractory Follicular Lymphoma

Immunotherapy Now First Line for Esophageal Cancer

FDA Approves Azacitidine for Newly Diagnosed Juvenile Myelomonocytic Leukemia

FDA Grants Regular Approval to Fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic HER2-Positive Breast Cancer

Bevacizumab Biosimilar Alymsys Gets FDA Approval

Phase 3 Clinical Trial Results Lead to Approval of Oral Drug for Red Blood Cell Disorder

header-info

Apr. 14, 2022

Researchers have published the results of a clinical trial that led the US Food and Drug Administration to recently approve mitapivat for the treatment of adults with pyruvate kinase deficiency...